NFE2L2 and non-small cell lung carcinoma: Since NRF2 activation by either loss-of-function mutation of KEAP1 or gain-of-function mutation of NRF2 is observed in approximately 30% of LUSC, the other major subtype of NSCLC (11), we also tested the therapeutic efficacy of DRP-104 in a LUSC PDX model (LX640) with KEAP1 mutation.